Exciting new developments emerge from the oncology and hematology fields constantly. While many changes unfold over time, some announcements, new discoveries, and novel products are unveiled at annual conferences. Major oncology conferences include those of the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO). Important hematology conferences include the […]

Immunotherapy with PD-1 and PD-L1 inhibitors has been a welcome addition to cancer treatment across numerous tumor types. While these agents are highly effective in some patients, they can be associated with severe, long-lasting adverse events (AEs). To better capture the incidence of AEs associated with PD-(L)1 inhibitors, a recent meta-analysis published in JAMA Oncology […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and essentially get to the why. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices along with leading scientific experts […]

On April 18, 2019, the United States Food and Drug Administration (FDA) issued a draft guidance for industry on the development of bispecific antibodies. This guidance outlines general considerations and recommendations for any new bispecific antibody development program, and also provides specific information regarding quality testing, nonclinical pharmacology and toxicology studies, clinical pharmacokinetic and pharmacodynamic […]

The fields of oncology and hematology are fast-paced. New studies are published every day, offering fresh information and insights into diseases and treatments. This emerging research changes the landscape of medical information on which clinicians base their decisions. In addition, doctors’ experiences and collaborations within clinics and hospitals evolve over time. This progression impacts how […]